Literature DB >> 12939742

There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability.

Rebecca Barnetson1, Robert Eckstein, Bruce Robinson, Margaret Schnitzler.   

Abstract

This study investigates the molecular features of metastasis in sporadic colon carcinomas with high-level microsatellite instability (MSI-H). DNA from 51 regions from 10 MSI-H metastatic carcinomas and 26 corresponding metastases was analyzed for mutations in TGFBRII, IGFIIR, BAX, MSH3, MSH6, and TCF4, which are associated with MSI-H carcinomas. In addition, 10 metastatic and 10 non-metastatic MSI-H carcinomas and 10 metastatic microsatellite-stable (MSS) carcinomas were examined for expression of vascular endothelial growth factor (VEGF) and mutant TP53. The frequency of microsatellite instability and somatic mutations was not significantly increased in the metastases compared with the that of primary carcinomas. Although significantly fewer MSI-H carcinomas expressed VEGF (P < 0.01) and mutant TP53 (P < 0.005) than MSS carcinomas, there was no difference in VEGF and mutant TP53 expression in metastatic and non-metastatic MSI-H carcinomas. In conclusion, metastasis does not appear to be associated with an increase in somatic mutation rate in any of the genes examined in MSI-H colon carcinomas. Furthermore, VEGF and TP53 expression did not appear to be involved in metastasis in MSI-H colon carcinomas. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939742     DOI: 10.1002/gcc.10262

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  2 in total

1.  Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2).

Authors:  Heekyung Chung; Joy Chaudhry; Jenny F Lai; Dennis J Young; John M Carethers
Journal:  Mutat Res       Date:  2011-10-05       Impact factor: 2.433

2.  Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.

Authors:  Saori Mishima; Hiroya Taniguchi; Kiwamu Akagi; Eishi Baba; Yutaka Fujiwara; Akira Hirasawa; Masafumi Ikeda; Osamu Maeda; Kei Muro; Hiroshi Nishihara; Hiroyki Nishiyama; Tadao Takano; Katsuya Tsuchihara; Yasushi Yatabe; Yasuhiro Kodera; Takayuki Yoshino
Journal:  Int J Clin Oncol       Date:  2019-07-08       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.